Partnering M118 now would be less risky and would enable multiple phase-2 trials to be conducted in parallel. This is especially vital for an anticoagulant, which typically needs to be tested in manifold settings to find the best fits.
Of course, the decision to partner or wait ultimately depends on the specific offers that come in.
Market Data 
Markets 
AI
